Floatz logo

gc1118

EGFR Amplification

Samsung Medical Centermonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the EGFR Amplification cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Bicara Therapeutics
Phase 1CC
Epirubicin
Bicara Therapeutics
Phase 1CC
Pembrolizumab
Bicara Therapeutics
Phase 1CC
Immunoglobulin G1 [de-C-terminal-lysine], anti-(human epidermal growth factor receptor) (human-Mus musculus clone BCA101 ?1-chain), disulfide with human-Mus musculus clone BCA101 ?-chain fusion protein with peptide linker (GGGGS)3 fusion protein with 23-159-transforming growth factor ? receptor TGFBR2 (human), dimer
Bicara Therapeutics
Phase 1CC
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Tianjin Medical University Second Hospital
N/AD

Same molecule, other indications

gc1118 is also rated in:

adult glioblastomaDormant
B
Indicative ·
57 / 100
View asset →
metastatic neoplasmDormant
C
Indicative ·
39 / 100
View asset →
gastric cancerDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →